The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 64 results
Sort by date: Descending
Encores: Not included
Schizophrenia
ASCP 2026 POSTER
Real-World Persistence on Olanzapine/Samidorphan Versus Other Oral Second-Generation Antipsychotics in Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Christoph U. Correll, MD,3-7 Rakesh Jain, MD, MPH,8 Craig Chepke, MD,9,10 Hara E. Oyedeji, DNP, PMHNP-BC,11 Alejandro G. Hughes, MPH,12 Noah S. Webb, PhD,12 Michael J. Doane, PhD,13 Hemangi R. Panchmatia, MSc13

View poster
Schizophrenia
Sleep-wake disorders
ISPOR 2026 POSTER
Real-World Experience and Burden of Cognitive Impairment in Narcolepsy and Idiopathic Hypersomnia: Survey Results From the ASPIRE Study
AUTHOR(S)

Michael J. Doane,1 Jane Lazar Tucker,2 Kristen McCausland,2 Lindsay Jesteadt,3,4 Claire Wylds-Wright3,4

View poster
Sleep-wake disorders
Sleep-wake disorders
ISPOR 2026 POSTER
Real-World Experience and Burden of Fatigue in Narcolepsy and Idiopathic Hypersomnia: Survey Results From the ASPIRE Study
AUTHOR(S)

Michael J. Doane,1 Jane Lazar Tucker,2 Kristen McCausland,2 Claire Wylds-Wright,3,4 Lindsay Jesteadt3,4

View poster
Sleep-wake disorders
Sleep-wake disorders
ISPOR 2026 POSTER
Real-World Symptoms and Impacts of Narcolepsy and Idiopathic Hypersomnia: Qualitative Results Using Social Media Listening Methods
AUTHOR(S)

Michael J. Doane,1 Danielle Altman,2 Kristi Jackson,2 Mitali Soni,2 Nana Y. Asiedu,2 Kristen McCausland2

View poster
Sleep-wake disorders
Bipolar Disorder
Schizophrenia
APA 2026 PRESENTATION
Olanzapine/Samidorphan Combination (OLZ/SAM) for Patients With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Christoph U. Correll,1-3 Andrew J. Cutler,4,5 Rakesh Jain,6 Hemangi R. Panchmatia,7 Barry Lubarsky7

View presentation
Bipolar Disorder
Schizophrenia
Sleep-wake disorders
AAN 2026 POSTER
Improvement in Patient-Reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type 1 Treated With Alixorexton, an Orexin 2 Receptor Agonist, in the Vibrance-1 Phase 2 study
AUTHOR(S)

Yves Dauvilliers,1 Ronald R. Grunstein,2,3 Emmanuel Mignot,4 Gert J. Lammers,5,6 David T. Plante,7 Erik Buntinx,8 Rafael del Río Víllegas,9,10 Hailu Chen,11 Craig Hopkinson,11 Bhaskar Rege,11 Julie Himes,11 Michael J. Doane,11 Giuseppe Plazzi12,13

View poster
Sleep-wake disorders